BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2170 related articles for article (PubMed ID: 15585641)

  • 21. 2-Arylthiazolidine-4-carboxylic acid amides (ATCAA) target dual pathways in cancer cells: 5'-AMP-activated protein kinase (AMPK)/mTOR and PI3K/Akt/mTOR pathways.
    Li CM; Narayanan R; Lu Y; Hurh E; Coss CC; Barrett CM; Miller DD; Dalton JT
    Int J Oncol; 2010 Oct; 37(4):1023-30. PubMed ID: 20811725
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma.
    Peponi E; Drakos E; Reyes G; Leventaki V; Rassidakis GZ; Medeiros LJ
    Am J Pathol; 2006 Dec; 169(6):2171-80. PubMed ID: 17148679
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activation of mammalian target of rapamycin in transformed B lymphocytes is nutrient dependent but independent of Akt, mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, insulin growth factor-I, and serum.
    Wlodarski P; Kasprzycka M; Liu X; Marzec M; Robertson ES; Slupianek A; Wasik MA
    Cancer Res; 2005 Sep; 65(17):7800-8. PubMed ID: 16140948
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rapamycin reverses NPM-ALK-induced glucocorticoid resistance in lymphoid tumor cells by inhibiting mTOR signaling pathway, enhancing G1 cell cycle arrest and apoptosis.
    Gu L; Gao J; Li Q; Zhu YP; Jia CS; Fu RY; Chen Y; Liao QK; Ma Z
    Leukemia; 2008 Nov; 22(11):2091-6. PubMed ID: 18685609
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of mammalian target of rapamycin reverses alveolar epithelial neoplasia induced by oncogenic K-ras.
    Wislez M; Spencer ML; Izzo JG; Juroske DM; Balhara K; Cody DD; Price RE; Hittelman WN; Wistuba II; Kurie JM
    Cancer Res; 2005 Apr; 65(8):3226-35. PubMed ID: 15833854
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Degradation of HER2 by ansamycins induces growth arrest and apoptosis in cells with HER2 overexpression via a HER3, phosphatidylinositol 3'-kinase-AKT-dependent pathway.
    Münster PN; Marchion DC; Basso AD; Rosen N
    Cancer Res; 2002 Jun; 62(11):3132-7. PubMed ID: 12036925
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-tumor effect of honokiol alone and in combination with other anti-cancer agents in breast cancer.
    Liu H; Zang C; Emde A; Planas-Silva MD; Rosche M; Kühnl A; Schulz CO; Elstner E; Possinger K; Eucker J
    Eur J Pharmacol; 2008 Sep; 591(1-3):43-51. PubMed ID: 18588872
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential insulin-like growth factor I receptor signaling and function in estrogen receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 breast cancer cells.
    Bartucci M; Morelli C; Mauro L; Andò S; Surmacz E
    Cancer Res; 2001 Sep; 61(18):6747-54. PubMed ID: 11559546
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Signal transduction pathways in androgen-dependent and -independent prostate cancer cell proliferation.
    Ghosh PM; Malik SN; Bedolla RG; Wang Y; Mikhailova M; Prihoda TJ; Troyer DA; Kreisberg JI
    Endocr Relat Cancer; 2005 Mar; 12(1):119-34. PubMed ID: 15788644
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MAP kinase/estrogen receptor cross-talk enhances estrogen-mediated signaling and tumor growth but does not confer tamoxifen resistance.
    Atanaskova N; Keshamouni VG; Krueger JS; Schwartz JA; Miller F; Reddy KB
    Oncogene; 2002 Jun; 21(25):4000-8. PubMed ID: 12037682
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma.
    Zhou Q; Lui VW; Lau CP; Cheng SH; Ng MH; Cai Y; Chan SL; Yeo W
    Biochem Pharmacol; 2012 May; 83(9):1146-58. PubMed ID: 22285225
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antiestrogen-resistant human breast cancer cells require activated protein kinase B/Akt for growth.
    Frogne T; Jepsen JS; Larsen SS; Fog CK; Brockdorff BL; Lykkesfeldt AE
    Endocr Relat Cancer; 2005 Sep; 12(3):599-614. PubMed ID: 16172194
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The rapamycin-derivative RAD001 (everolimus) inhibits cell viability and interacts with the Akt-mTOR-p70S6K pathway in human medullary thyroid carcinoma cells.
    Grozinsky-Glasberg S; Rubinfeld H; Nordenberg Y; Gorshtein A; Praiss M; Kendler E; Feinmesser R; Grossman AB; Shimon I
    Mol Cell Endocrinol; 2010 Feb; 315(1-2):87-94. PubMed ID: 19815051
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Increased constitutive activity of PKB/Akt in tamoxifen resistant breast cancer MCF-7 cells.
    Jordan NJ; Gee JM; Barrow D; Wakeling AE; Nicholson RI
    Breast Cancer Res Treat; 2004 Sep; 87(2):167-80. PubMed ID: 15377841
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 15(S)-hydroxyeicosatetraenoic acid induces angiogenesis via activation of PI3K-Akt-mTOR-S6K1 signaling.
    Zhang B; Cao H; Rao GN
    Cancer Res; 2005 Aug; 65(16):7283-91. PubMed ID: 16103079
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Activation of phosphatidylinositol 3-kinase, Akt, and mammalian target of rapamycin is necessary for hypoxia-induced pulmonary artery adventitial fibroblast proliferation.
    Gerasimovskaya EV; Tucker DA; Stenmark KR
    J Appl Physiol (1985); 2005 Feb; 98(2):722-31. PubMed ID: 15501927
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The antitumor effect of GDC-0941 alone and in combination with rapamycin in breast cancer cells.
    Zheng J; Zou X; Yao J
    Chemotherapy; 2012; 58(4):273-81. PubMed ID: 23006739
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells.
    Knuefermann C; Lu Y; Liu B; Jin W; Liang K; Wu L; Schmidt M; Mills GB; Mendelsohn J; Fan Z
    Oncogene; 2003 May; 22(21):3205-12. PubMed ID: 12761490
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of mTOR inhibition alone or combined with MEK inhibitors on brain metastasis: an in vivo analysis in triple-negative breast cancer models.
    Zhao H; Cui K; Nie F; Wang L; Brandl MB; Jin G; Li F; Mao Y; Xue Z; Rodriguez A; Chang J; Wong ST
    Breast Cancer Res Treat; 2012 Jan; 131(2):425-36. PubMed ID: 21394501
    [TBL] [Abstract][Full Text] [Related]  

  • 40. TOR kinase and Ran are downstream from PI3K/Akt in H2O2-induced mitosis.
    Radisavljevic ZM; González-Flecha B
    J Cell Biochem; 2004 Apr; 91(6):1293-300. PubMed ID: 15048882
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 109.